Thoratec Cp: (NASD: THOR)

$30.97

-0.55 (-1.75%)

Volume 821,682

May 22 04:00 PM ET

Zacks Rank: 4-Sell

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		30.85 - 31.85
	
		52wk Low - High
		29.39 - 39.86
	
		Previous Close
		31.52
	
		Avg. Volume
		1,062,791
	
		Industry
		MED INSTRUMENTS
	
		Market Cap
		1.82 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.76
	
		PE (Forward)
		20.33
	
		Current Year Est.
		1.55
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		4
Sell

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Underperform
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		113 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/20/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            20.33
                        
                            PEG Ratio
                            2.01
                        
                            Current Year Est.
                            1.55
                        
                            Current Quarter Estimate
                            0.35
                        
                            Most Accurate Estimate
                            0.35
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-07-2013
                        
                            EPS Last Year
                            1.51
                        
                            Expected Earnings Growth
                            10.11%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Thoratec Corp develops, manufactures and markets proprietary medical devices used for circulatory support, vascular graft, blood coagulation and skin incision applications.  They currently market the Thoratec Ventricular Assist Device System (called Thoratec VAD System or VAD System) and the HeartMate Left Ventricular Assist System (called HeartMate LVAS) in the United States and internationally for use as a bridge to heart transplant.  They have also developed small diameter vascular grafts for use in hemodialysis access and coronary artery bypass surgery.   
Full THOR Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
THOR Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.35	0.41	1.55	1.75
Number of Estimates	1	1	1	1
Low Estimate	0.35	0.41	1.55	1.75
High Estimate	0.35	0.41	1.55	NA
Year Ago EPS	0.39	0.44	1.60	1.55
EPS Growth	-10.26%	-6.82%	-3.13%	12.90%

More THOR Estimates

Average Earnings Estimates for THOR

EPS Growth for THOR

Industry Analysis

Name	Symbol	Previous Close
THORATEC CORP	THOR	31.52
NATUS MEDICAL	BABY	15.11
CRYOLIFE INC	CRY	6.49
DELCATH SYS INC	DCTH	0.44
GLOBUS MEDICAL	GMED	15.82
HEARTWARE INTL	HTWR	95.05
INTUITIVE SURG	ISRG	485.88
MELA SCIENCES	MELA	1.09
OXYSURE SYSTEMS	OXYS	0.82
PACIFIC BIOSCI	PACB	2.54

Sector:Medical>> Industry:MED INSTRUMENTS

COMPARE TICKER vs. Its Peers

Zacks Commentary

THOR Downgraded to Underperform

May 21, 2013

FDA Nod for Thoratec Controller

May 20, 2013

Thoratec Misses Earnings and Rev Est

May 06, 2013

Thoratec Upgraded to Neutral

Apr 12, 2013

Thoratec Reveals Human Use of PHP

Mar 20, 2013

Zacks Rank #5 Additions for Friday

Feb 08, 2013

Thoratec Beats, Posts Loss

Feb 06, 2013

Thoratec Downgraded to Neutral

Jan 15, 2013

More THOR Zacks Commentary

Financials

EPS TTM	1.51
Sales	492
Net Income	49
Price/Earnings	20.87
Price/Book	2.94
Price/Cash Flow	15.77
Price/Sales	3.76

More THOR Financials

News

WEALTHMAKERS.COM Issues Bearish Research Reports on MAC, NNI, OSH, PLAB, PRMW, THOR - M2

May 22, 2013

Analysis of Relative Performance in the Health Care Equipment Industry for Shares of Thoratec (THOR, HTWR, EW, ABMD, CFN) - Financial News Network Online - News Corner

May 21, 2013

Thoratec (THOR) Showing Bearish Technicals But Could Fall Through $30.72 Support - Freshbrewedmedia

May 21, 2013

WEALTHMAKERS.COM Issues Bearish Research Reports on ALNY, HOFT, JCP, NEU, THOR - M2

May 21, 2013

Benzinga`s Top Downgrades - Benzinga

May 20, 2013

Downgrade Alert for Thoratec (THOR) - Comtex Smartrend(R)

May 20, 2013

Shares of Thoratec Are Moving Lower on 1.2x Above-Average Volume (THOR) - Financial News Network Online - Unusual Volume

May 20, 2013

Stock Investors Sell Off Shares of Thoratec, Down 3.6% - Financial News Network Online - Market Movers

May 20, 2013

See All News Stories on THOR

Broker Recommendations

Current ABR	1.93
ABR (Last Week)	1.93
# of recs in ABR	15
Average Target Price	39.69
Industry Rank by ABR	113 out of 265
Rank in Industry	46 out of 54

More THOR Broker Recommendations

Day Low - High	30.85 - 31.85
52wk Low - High	29.39 - 39.86
Previous Close	31.52
Avg. Volume	1,062,791
Industry	MED INSTRUMENTS
Market Cap	1.82 B
Div - Yield	0.00 - 0.00
Beta	0.76
PE (Forward)	20.33
Current Year Est.	1.55
Quarterly Earnings ESP	0.00%

PE (Forward)	20.33
PEG Ratio	2.01
Current Year Est.	1.55
Current Quarter Estimate	0.35
Most Accurate Estimate	0.35
Earnings ESP	0.00%
Next Earnings Report Date	08-07-2013
EPS Last Year	1.51
Expected Earnings Growth	10.11%

Username: Password:

Remember me [?]

Thoratec Cp: (NASD: THOR)

$30.97

-0.55 (-1.75%)

Volume 821,682

May 22 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED INSTRUMENTS

Zacks Commentary

Financials

News

Broker Recommendations